Sugentech Inc (253840) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sugentech Inc (253840) has a cash flow conversion efficiency ratio of -0.059x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.25 Billion ≈ $-2.88 Million USD) by net assets (₩72.28 Billion ≈ $48.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Sugentech Inc's balance sheet to measure how much of total assets are equity-financed.
Sugentech Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Sugentech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Sugentech Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Sugentech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sugentech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acorn Energy, Inc. Common Stock
NASDAQ:ACFN
|
0.006x |
|
Harbour Energy PLC
LSE:HBR
|
0.380x |
|
Simonds Group Ltd
AU:SIO
|
0.605x |
|
BrilliA Inc
NYSE MKT:BRIA
|
N/A |
|
Fiyta Holdings Ltd
SHE:200026
|
0.040x |
|
WHA Business Complex Freehold and Leasehold Real Estate Investment Trust
BK:WHABT
|
0.011x |
|
SAMRYOONG Co.Ltd
KQ:014970
|
0.052x |
|
Yangjisa Co. Ltd
KQ:030960
|
0.006x |
Annual Cash Flow Conversion Efficiency for Sugentech Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Sugentech Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see 253840 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩76.54 Billion ≈ $51.87 Million |
₩-14.65 Billion ≈ $-9.93 Million |
-0.191x | -147.24% |
| 2024-12-31 | ₩97.13 Billion ≈ $65.82 Million |
₩-7.52 Billion ≈ $-5.09 Million |
-0.077x | +28.39% |
| 2023-12-31 | ₩112.45 Billion ≈ $76.21 Million |
₩-12.15 Billion ≈ $-8.24 Million |
-0.108x | -149.93% |
| 2022-12-31 | ₩140.58 Billion ≈ $95.27 Million |
₩30.43 Billion ≈ $20.62 Million |
0.216x | -44.04% |
| 2021-12-31 | ₩100.71 Billion ≈ $68.25 Million |
₩38.96 Billion ≈ $26.40 Million |
0.387x | +67.51% |
| 2020-12-31 | ₩63.11 Billion ≈ $42.77 Million |
₩14.57 Billion ≈ $9.87 Million |
0.231x | +239.92% |
| 2019-12-31 | ₩24.31 Billion ≈ $16.47 Million |
₩-4.01 Billion ≈ $-2.72 Million |
-0.165x | +18.61% |
| 2018-12-31 | ₩15.46 Billion ≈ $10.47 Million |
₩-3.13 Billion ≈ $-2.12 Million |
-0.203x | -831.42% |
| 2017-12-31 | ₩-32.81 Billion ≈ $-22.24 Million |
₩-909.59 Million ≈ $-616.42K |
0.028x | -- |
About Sugentech Inc
Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2… Read more